Periasamy Selvaraj received his Ph.D. in India and did his postdoctoral in Immunology at Dana Farber Cancer Institute, Harvard Medical School, Boston. Currently, Dr. Selvaraj is a Professor of Pathology in the School of Medicine of the Emory University at Atlanta, GA. His laboratory focuses on developing cancer vaccines using novel protein transfer approaches. He has published more than 90 research papers in national and international journals. Dr. Selvaraj also serves as Chief Scientific Officer and Co-founder of Metaclipse Therapeutics Corporation, a biotech company focusing on developing personalized immunotherapy for metastatic cancer. Periasamy Selvaraj received his Ph.D. in India and did his postdoctoral in Immunology at Dana Farber Cancer Institute, Harvard Medical School, Boston. Currently, Dr. Selvaraj is a Professor of Pathology in the School of Medicine of the Emory University at Atlanta, GA. His laboratory focuses on developing cancer vaccines using novel protein transfer approaches. He has published more than 90 research papers in national and international journals. Dr. Selvaraj also serves as Chief Scientific Officer and Co-founder of Metaclipse Therapeutics Corporation, a biotech company focusing on developing personalized immunotherapy for metastatic cancer.

Vaccine,Immunology